INmune Bio, Inc.
INMB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $14 | $155 | $374 | $181 |
| % Growth | -91% | -58.6% | 106.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $14 | $155 | $374 | $181 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $33,166 | $20,273 | $17,067 | $20,543 |
| G&A Expenses | $9,483 | $9,623 | $9,258 | $8,791 |
| SG&A Expenses | $9,483 | $9,623 | $9,258 | $8,791 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $42,649 | $29,896 | $26,325 | $29,334 |
| Operating Income | -$42,635 | -$29,741 | -$25,951 | -$29,153 |
| % Margin | -304,535.7% | -19,187.7% | -6,938.8% | -16,106.6% |
| Other Income/Exp. Net | $553 | -$267 | -$1,348 | -$1,187 |
| Pre-Tax Income | -$42,082 | -$30,008 | -$27,299 | -$30,340 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$42,082 | -$30,008 | -$27,299 | -$30,340 |
| % Margin | -300,585.7% | -19,360% | -7,299.2% | -16,762.4% |
| EPS | -2.11 | -1.67 | -1.52 | -1.88 |
| % Growth | -26.3% | -9.9% | 19.1% | – |
| EPS Diluted | -2.11 | -1.67 | -1.52 | -1.88 |
| Weighted Avg Shares Out | 19,944 | 17,981 | 17,927 | 16,131 |
| Weighted Avg Shares Out Dil | 19,944 | 17,981 | 17,927 | 16,131 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $553 | $29,741 | $25,951 | $29,153 |
| EBITDA | -$42,082 | $0 | $0 | $0 |
| % Margin | -300,585.7% | 0% | 0% | 0% |